NCT02538614View on ClinicalTrials.gov

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Idelalisib

Tablets administered orally twice daily

DRUG

BI 836826

Intravenous administration as a rate-controlled infusion

Trial Locations (2)

Unknown

Ohio State University, Columbus

University of Utah, Salt Lake City

Sponsors

Lead Sponsor

Gilead Sciences

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Gilead Sciences

INDUSTRY